Michael Friedman - Celgene Independent Director
Director
Dr. Michael A. Friedman, M.D., is Independent Director of Celgene Corporationration Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organizations Comprehensive Cancer Center and holder of the Irell Manella Cancer Center Directors Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of Californias stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporationrationration, Smith Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University since 2011.
| Age | 73 |
| Tenure | 13 years |
| Phone | 908 673-9000 |
| Web | www.celgene.com |
Celgene Management Efficiency
The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stephen Lanning | National CineMedia | 62 | |
| Harry Wilson | Visteon Corp | 46 | |
| Duncan Cocroft | Visteon Corp | 71 | |
| Kam Yuen | Visteon Corp | 69 | |
| Lawrence Goodman | National CineMedia | 63 | |
| Lee Mitchell | National CineMedia | 81 | |
| Kristopher Doyle | Visteon Corp | N/A | |
| James Barrese | Visteon Corp | 50 | |
| Bryan Wiener | Cars Inc | 49 | |
| Robert Manzo | Visteon Corp | 61 | |
| Paula Madison | National CineMedia | 63 | |
| Joanne Maguire | Visteon Corp | 65 | |
| David Wiadrowski | CarsalesCom Ltd ADR | N/A | |
| Jeffrey Browne | CarsalesCom Ltd ADR | 63 | |
| David Treadwell | Visteon Corp | 64 | |
| Naomi Bergman | Visteon Corp | 55 | |
| Chris Polites | CarsalesCom Ltd ADR | N/A | |
| Michael Kelly | Cars Inc | 63 | |
| David Haas | National CineMedia | 76 | |
| Bala Subramanian | Cars Inc | 49 | |
| Donald McGovern | Cars Inc | 69 | |
Management Performance
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 |
Celgene Leadership Team
Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Loughlin, Independent Director | ||
| Michael Friedman, Independent Director | ||
| Michael Bonney, Director | ||
| Hans Bishop, Director | ||
| John Weiland, Director | ||
| Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary | ||
| Gilla Kaplan, Independent Director | ||
| Patricia Hall, Director | ||
| Robert Hugin, Chairman of the Board and Presidentident, CEO | ||
| Peter Kellogg, CFO, Executive Vice President | ||
| David Elkins, Executive Vice President | ||
| Perry Karsen, CEO of Celgene Cellular Therapeutics | ||
| Rupert Vessey, President - Research and Early Development | ||
| Carrie Cox, Independent Director | ||
| Terrie Curran, President Global Inflammation & Immunology Franchise | ||
| Michael Pehl, President Hematology & Oncology | ||
| Mark Alles, President, COO and Director | ||
| Alise Reicin, President - Global Clinical Development | ||
| Jonathan Biller, Executive Vice President General Counsel | ||
| Julia Haller, Director | ||
| Robert Hershberg, Chief Scientific Officer | ||
| Jacqualyn Fouse, President of Global Hematology and Oncology and Director | ||
| Ernest Mario, Independent Director | ||
| Scott Smith, President - Inflammation & Immunology | ||
| Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development | ||
| Richard Barker, Independent Director | ||
| Michael Casey, Lead Independent Director |
Celgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X |
Pair Trading with Celgene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to First Horizon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace First Horizon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back First Horizon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling First Horizon National to buy it.
The correlation of First Horizon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as First Horizon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if First Horizon National moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for First Horizon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |